Parkinson's disease, DBS and FDA

FDA OKs First Adaptive DBS System for Parkinson’s Disease
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized neuromodulation that responds to the patient’s changing needs.
FDA approves Medtronic’s brain stimulation system for Parkinson’s
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
Medtronic wins first FDA nod for adaptive DBS for Parkinson’s
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI).
FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.
FDA Approves Medtronic’s BrainSense Adaptive Deep Brain Stimulation for Parkinson Disease
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.
FDA approves Medtronic’s adaptive deep-brain stimulator for Parkinson’s disease
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation ap | The company said its U.
Medtronic’s BrainSense brain stimulation system approved by FDA for Parkinson’s
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no
Medtronic plc: Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
News Medical21m
FDA-approved technology offers personalized treatment for Parkinson’s symptoms
Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.
Medtronic’s CEO says, “We’ve got to be an ‘and’ company”
Earlier this year, Medtronic received approval from European regulators for its adaptive deep brain stimulation (aDBS) technology, which includes an implant that can dynamically adjust signals to ...